Koers RegeneRx Biopharmaceuticals, Inc. Other OTC
Aandelen
RGRX
US75886X1081
Farmaceutische producten
Omzet 2021 | 76,76K 70,7K | Omzet 2022 | 76,76K 70,7K | Marktkapitalisatie | 19,94 mln. 18,37 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2021 | -1 mln. -921K | Nettowinst (verlies) 2022 | -1 mln. -921K | EV/omzet 2021 | 298 x |
Nettoliquiditeiten 2021 | 66,69K 61,43K | Nettoschuld 2022 | 1,16 mln. 1,06 mln. | EV/omzet 2022 | 275 x |
K/w-verhouding 2021 |
-13,9
x | K/w-verhouding 2022 |
-11,5
x | Werknemers | - |
Dividendrendement 2021 * |
-
| Dividendrendement 2022 |
-
| Vrij verhandelbaar | 55,86% |
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Founder | 86 | 13-05-82 | |
J. Finkelstein
CEO | Chief Executive Officer | 72 | 01-01-84 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
J. Finkelstein
CEO | Chief Executive Officer | 72 | 01-01-84 |
Founder | 86 | 13-05-82 | |
Joe McNay
BRD | Director/Board Member | 90 | 01-01-02 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
-3,02% | 89,69 mld. | |
+2,50% | 41,34 mld. | |
-12,01% | 33,72 mld. | |
+62,74% | 26,11 mld. | |
-19,79% | 14,63 mld. | |
-8,58% | 12,84 mld. | |
-12,34% | 11,66 mld. | |
-43,92% | 11,52 mld. | |
+4,27% | 8,92 mld. |